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SHORT COMMUNICATION
Photodynamic therapy with daylight (DL-PDT) is a pro-
mising treatment modality for actinic keratoses (AK). It 
enables the convenient and painless treatment of large 
areas of photo-damaged skin, and has excellent cosmetic 
outcome. DL-PDT using methyl-5-aminolaevulinate 
(MAL) has shown equal efficacy with conventional 
light-emitting diodes (LED)-PDT (1–3). However, all 
the current studies of DL-PDT have limited follow-up 
periods of 3 or 6 months (1–5). As AKs tend to regress 
spontaneously and reoccur over time (6), it is crucial to 
determine the long-term efficacy of treatment. In our 
previously published non-sponsored, randomized, dou-
ble-blinded, prospective pilot trial, amino-5-laevulinate 
nanoemulsion (BF-200 ALA) showed a trend towards 
improved efficacy compared with MAL in DL-PDT 
for AKs (7). We report here the long-term (12-month) 
clinical and histological outcomes of the same pilot trial.
MATERIALS AND METHODS
The methods have been described previously in detail (7). Pa-
tients with symmetrical actinic damage in the head area who 
volunteered to enter the study, were treated in August and Sep-
tember 2013. Prior to treatment, all lesions were photographed, 
counted and marked on a plastic sheet, and 2 symmetrical equally 
graded (8) AKs were biopsied bilaterally. A chemical sunscreen 
(P20®, SPF 20 Riemann & C0. A/S, Hilleroed, Denmark) was 
applied and after 15 min the treatment areas were curettaged 
followed by application of the photosensitizers (0.25-mm thick 
layer). Patients were randomized to receive DL-PDT with BF-
200 ALA (Ameluz, Biofrontera, Leverkusen, Germany) on one 
side of the face or scalp and MAL (Metvix, Galderma, Paris) 
on the other with 2-h illumination outdoors. Follow-up visits, 
conducted by the same blinded investigator (MG), included the 
mapping of the residual lesions, as well as histological sampling. 
Histology was interpreted by a blinded pathologist (TTT). For 
statistical analysis the following tests were used: Wilcoxon’s 
signed-rank paired test: baseline characteristics, lesion clearance, 
area complete response, histological clearance, reduction in p53; 
and McNemar’s test: complete field clearance.
RESULTS
All 13 patients in the initial 3-month analyses conti-
nued to follow-up at 12 months. Between the 3- and 
12-month control visits one grade I AK in the MAL 
group and two grade II AKs in the BF-200 ALA area 
were treated using cryosurgery, as requested by the 
patients. Of these, the lesion in the MAL group was still 
present at 12 months, while the lesions in the BF-200 
ALA group cleared. Other lesions were treated only 
after the 12-month follow-up.
At 12 months in per patient half-face analysis, 9 of 
the 13 (69.2%, 95% confidence interval (CI) 44.1–94.3) 
fields treated with BF-200 ALA and 3 of 13 (23.1%, 95% 
CI 0.2–46.0) fields treated with MAL were completely 
cleared of AKs (p = 0.07). The mean complete lesion 
clearance rate per patient (half-face) was 87% for BF-
200 ALA and 62% for MAL (p = 0.007) (Table I). The 
medians (percentiles 25 and 75) for lesion clearance were 
100 (73.2, 100) for BF-200 ALA and 60 (41.7, 90.9) for 
MAL. The area complete response including the baseline 
and new lesions (preventive effect) were 83.3% for BF-
200 ALA and 59.1% for MAL (p = 0.0021).
If we assume that no lesion had been treated with 
cryosurgery before the 12-month follow-up (and were 
still present at 12 months) the clearance rates would 
have been as follows: mean complete lesion clearance 
rate per patient (half-face) 83% vs. 62% (p = 0.055) and 
area complete response 81% vs. 59.1% (p = 0.0071), for 
BF-200 ALA and MAL, respectively.
For histological analysis, one AK lesion on both 
treatment sides was biopsied before treatment, and the 
same area was biopsied again at 3 and 12 months. One 
patient who was clinically completely cleared refused 
histological sampling at the 12-month visit. Thus, 12 
patients were biopsied bilaterally after 12 months. 
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CRdBase line 12 mo.
BF-200 amino-5-laevulinate
  Total 84 14   8   6 0 87% 83.3%
  Grade I 61 13   8   5
  Grade II–III 23   1   0   1
Methyl-5-aminolaevulinate
  Total 93 38 18 16 4 62% 59.1%
  Grade I 73 34 15 15 4
  Grade II–III 20   4   3   1 0
p-values 0.496 0.007 0.0021
aRes.: Residual. Lesions present at baseline, 3- and 12-month follow-up. bRec.: 
Recurrent. Lesions present at baseline, cleared at 3 months and reoccurred at 
12 months. cMean complete clearence of lesions, per patient. dArea complete 
response (CR) includes the residual and new lesions.
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The complete histological clearance rates were 6 of 12 
(50%) for BF-200 ALA and 5 of 12 (41.6%) for MAL 
(p = 0.417). Surprisingly, at 12 months, mean p53 expres-
sion was 45.4% of the baseline level in the BF-200 ALA 
group, while it had increased to 96% in the MAL group 
(p = 0.182) (Fig. 1). 
DISCUSSION
The results of this study show, for the first time, the 
long-term (12 months) efficacy of DL-PDT. They sug-
gest that, in a long-term follow-up, BF-200 ALA is 
more effective compared with MAL in the treatment 
of AKs with DL-PDT. Our planned next step is to see 
if this result can be confirmed in a larger trial.
At 12 months, BF-200 ALA showed better maintained 
clearance than MAL. As we used an intra-patient study 
design, the per patient field response rates (69% for BF-
200 ALA and 23% for MAL) are indicative of the patient 
complete response rates. Interestingly, the depressed p53 
expression only minimally increased between 3 and 12 
months after treatment in the BF-200 ALA group while 
in the MAL group p53 expression was increased close to 
the baseline level. This may indicate a better long-term 
reversal in the carcinogenesis with BF-200 ALA. How-
ever, the same finding of better reversal in carcinogenesis 
was not seen in the HE-stainings, which may be due to 
the small sample size. Potentially better reversal in car-
cinogenesis in BF-200 ALA group is also supported by 
the fact that the MAL group developed more new lesions 
after 3 and 12 months than the BF-200 ALA group. AK 
counts can also change spontaneously, with high regres-
sion and recurrence rates (6). Thus, it is important not only 
to report the clearance of the baseline lesions, but also the 
preventive effect on the whole treated field. For this, we 
used an experimental analysis of area complete response.
A limitation of this study was the small sample size, 
including only 13 patients, and that a few lesions were 
treated between the 3- and 12-month follow-ups. How ever, 
this was taken into account when interpreting the results. 
In conclusion, in 12-month follow-up, DL-PDT with 
BF-200 ALA shows improved efficacy compared with 
MAL.
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Fig. 1. Mean p53 expression (%) prior to and after photodynamic therapy with 
daylight for actinic keratoses, in the presence of methyl-5-aminolaevulinate 
(MAL) or amino-5-laevulinate (BF-200 ALA) nanoemulsion.
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